XIPERE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Xipere, and when can generic versions of Xipere launch?
Xipere is a drug marketed by Bausch And Lomb Inc and is included in one NDA. There are three patents protecting this drug.
This drug has eighty-one patent family members in eighteen countries.
The generic ingredient in XIPERE is triamcinolone acetonide. There are fifty-one drug master file entries for this compound. Seventy suppliers are listed for this compound. Additional details are available on the triamcinolone acetonide profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Xipere
A generic version of XIPERE was approved as triamcinolone acetonide by TARO on October 1st, 1986.
Summary for XIPERE
| International Patents: | 81 |
| US Patents: | 3 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 83 |
| Patent Applications: | 4,203 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for XIPERE |
| What excipients (inactive ingredients) are in XIPERE? | XIPERE excipients list |
| DailyMed Link: | XIPERE at DailyMed |
Pharmacology for XIPERE
| Drug Class | Corticosteroid |
| Mechanism of Action | Corticosteroid Hormone Receptor Agonists |
Anatomical Therapeutic Chemical (ATC) Classes for XIPERE
US Patents and Regulatory Information for XIPERE
XIPERE is protected by three US patents and one FDA Regulatory Exclusivity.
Patents protecting XIPERE
Methods and devices for drug delivery to ocular tissue using microneedle
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF MACULAR EDEMA ASSOCIATED WITH UVEITIS
Methods and devices for the treatment of ocular diseases in human subjects
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF MACULAR EDEMA ASSOCIATED WITH UVEITIS
Apparatus and methods for ocular injection
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
FDA Regulatory Exclusivity protecting XIPERE
NEW PRODUCT
Exclusivity Expiration: ⤷ Sign Up
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bausch And Lomb Inc | XIPERE | triamcinolone acetonide | SUSPENSION;INJECTION | 211950-001 | Oct 22, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Bausch And Lomb Inc | XIPERE | triamcinolone acetonide | SUSPENSION;INJECTION | 211950-001 | Oct 22, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Bausch And Lomb Inc | XIPERE | triamcinolone acetonide | SUSPENSION;INJECTION | 211950-001 | Oct 22, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Bausch And Lomb Inc | XIPERE | triamcinolone acetonide | SUSPENSION;INJECTION | 211950-001 | Oct 22, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for XIPERE
See the table below for patents covering XIPERE around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Australia | 2013342275 | Methods and devices for the treatment of ocular diseases in human subjects | ⤷ Sign Up |
| Canada | 3121763 | METHODS AND DEVICES FOR THE TREATMENT OF OCULAR DISEASES IN HUMAN SUBJECTS | ⤷ Sign Up |
| China | 104921868 | Methods and Devices for Drug Delivery to Ocular Tissue Using Microneedle | ⤷ Sign Up |
| Japan | 5996526 | ⤷ Sign Up | |
| Eurasian Patent Organization | 201590902 | СПОСОБЫ И УСТРОЙСТВА, ПРИМЕНЯЕМЫЕ ДЛЯ ЛЕЧЕНИЯ ГЛАЗНЫХ БОЛЕЗНЕЙ У ЧЕЛОВЕКА | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
